In this scenario, genetic predisposition toward ADRs is an emerging issue, not only in anticancer chemotherapy, but also in many other fields of contemporary medicine, including glucose-6-phosphate dehydrogenase (G6PD) deficiency, malignant hyperthermia, epidermal tissue necrosis (Lyell’s Syndrome and Stevens-Johnson Syndrome), epilepsy, thyroid diseases, porphyria, aplastic anemia, Long QT Syndrome, and Brugada Syndrome (Swen et al., 2011; García-González et al., 2016; Weitzel et al., 2017). Here, G6PD is linked to Brugada syndrome.